Show simple item record

dc.contributor.authorMoradpour, Z
dc.contributor.authorGhasemian, A
dc.date.accessioned2018-08-26T08:06:39Z
dc.date.available2018-08-26T08:06:39Z
dc.date.issued2011
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/50060
dc.description.abstractResearchers increasingly believe that microbial, molecular and synthetic biology techniques along with genetic engineering will facilitate the treatment of persistent infectious diseases. However, such therapy has been plagued by the emergence of antibiotic-resistant bacteria, resulting in significant obstacles to treatment. Phage therapy is one promising alternative to antibiotics, especially now that recent modifications to ubiquitous phages have made them more controllable. Additionally, convincing in vitro and in vivo studies of genetically modified lytic phages and engineered non-lytic phages have confirmed the advantages of novel, specific bactericidal agents over antibiotics in some cases. There is still a need for a better understanding of phage therapy, however, before it can be adopted widely. (C) 2011 Elsevier Inc. All rights reserved.
dc.language.isoEnglish
dc.relation.ispartofBIOTECHNOLOGY ADVANCES
dc.subjectPhage therapy
dc.subjectModified phages
dc.subjectBacterial resistance
dc.titleModified phages: Novel antimicrobial agents to combat infectious diseases
dc.typeReview
dc.citation.volume29
dc.citation.issue6
dc.citation.spage732
dc.citation.epage738
dc.citation.indexWeb of science
dc.identifier.DOIhttps://doi.org/10.1016/j.biotechadv.2011.06.003


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record